[Pe-022] 一般演題ポスターセッション（英語）022

[Pe-022-1] COMET: Efficacy & safety of avalglucosidase alfa after 145 weeks in late-onset Pompe disease (LOPD) [Encore Presentation]

池田 光伸¹, Kishnani Priya S.², Diaz-Manera Jordi³, Dimachkie Mazen M.⁴, Schoser Benedikt⁵, on behalf of the COMET Investigator Group⁶ (1.サノフィ株式会社, 2.Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA, 3.John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK, 4.University of Kansas Medical Center, Department of Neurology, Kansas City, KS, USA, 5.Friedrich-Baur-Institute, Department of Neurology, LMU Klinikum Munchen, Munchen, Germany, 6.on behalf of the COMET Investigator Group)